Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Non Operating Income: 2019-2025

Historic Other Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$81,000.

  • Allogene Therapeutics' Other Non Operating Income rose 92.79% to -$81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year increase of 77.71%. This contributed to the annual value of -$3.9 million for FY2024, which is 78.02% up from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Other Non Operating Income is -$81,000, which was down 88.37% from -$43,000 recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Other Non Operating Income peaked at $2.1 million during Q1 2023, and registered a low of -$6.9 million during Q4 2023.
  • For the 3-year period, Allogene Therapeutics' Other Non Operating Income averaged around -$1.5 million, with its median value being -$929,000 (2024).
  • As far as peak fluctuations go, Allogene Therapeutics' Other Non Operating Income crashed by 651.22% in 2022, and later skyrocketed by 125.03% in 2023.
  • Allogene Therapeutics' Other Non Operating Income (Quarterly) stood at -$1.8 million in 2021, then plummeted by 101.27% to -$3.6 million in 2022, then crashed by 90.65% to -$6.9 million in 2023, then soared by 71.85% to -$2.0 million in 2024, then skyrocketed by 92.79% to -$81,000 in 2025.
  • Its Other Non Operating Income stands at -$81,000 for Q3 2025, versus -$43,000 for Q2 2025 and $92,000 for Q1 2025.